{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-084086","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2026-07-16T11:53:02+00:00","discovered_at":"2026-07-16T11:55:00.203563+00:00","generated_at":"2026-07-16T11:55:04.442419+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Gain Therapeutics updates cash runway; expects funding into Q2 2027","bullets":["Cash and equivalents expected to fund operations into Q2 2027 based on current plans.","Phase 1b open-label extension completion expected in October 2026.","Phase 2 clinical study initiation planned for Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-084086","json":"https://secwatch.observer/filing/0001104659-26-084086.json","markdown":"https://secwatch.observer/filing/0001104659-26-084086.md","text":"https://secwatch.observer/filing/0001104659-26-084086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926084086/0001104659-26-084086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926084086/tm2620618d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T11:55:04.442419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}